Pulmovant
Pulmovant is seeking a knowledgeable, cross-functional drug development program manager to support management of development programs, with a current focus on supporting studies within the PH-ILD program for mosliciguat. This role serves as a trusted point of contact for program communication between key functional teams, internal and external stakeholders, and senior leadership. The Program Manager will maintain timelines to ensure program deliverables are met on time and within budget.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant didn’t post a salary, so this is our estimate from similar listings.
18% below the average for this role
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago